Furosemide is a widely used, potent natriuretic drug, which inhibits the Na + -K + -2Cl -33 cotransporter (NKCC)-2 in the ascending limb of the loop of Henle applied to reduce 34 extracellular fluid volume expansion in heart and kidney disease. Modulation of the intrarenal renin angiotensin system, however, is ill-defined. Regarding 43 systemic effects, vasodilation followed by non-specific NKCC inhibition and changes in 44 venous compliance are not well understood. Repetitive administration of furosemide 45 induces short-term (braking phenomenon, acute diuretic resistance) and long-term 46 (chronic diuretic resistance) adaptations, of which the mechanisms are not well known. 47
The gene encoding for the Na + -K + -2Cl --cotransporter has two isoforms, NKCC1 and NKCC2. 126
The NKCC1 isoform is present in a wide variety of tissues, including the basolateral 127 membrane of secretory epithelia, smooth muscle cells, fibroblasts and red blood cells (55) . arterial pressure in animals treated with furosemide, but without volume repletion (159) ; 164 this was accompanied by a decrease in SNGFR, surprisingly mediated by a decrease in 165 glomerular permeability coefficient LpA, but not by a decrease in net ultrafiltration 166 pressure (159) . Surprisingly, Costa et al. reported similar decreases in MAP after 167 furosemide administration in rats in normovolemic versus volume-expanded animals (33). 168
To complicate this further, furosemide could elicit a natriuresis in an individual with 169 decompensated heart failure leading to a more favourable end-diastolic pressure and 170 increased cardiac output (98). Clearly, a decrease in blood pressure and renal perfusion 171 pressure will limit the diuretic actions of the drug, yet, whether this happens under 172 normovolemic and hypervolemic states is not well characterized. 173 174 Activation of the RAS is similarly complex. While there is ample data to support that 175 furosemide leads to increases in circulating levels of renin, data documenting how 176 furosemide (and other diuretics) affect components of the intrarenal RAS is absent. This is 177 particularly relevant with respect to intratubular and intrarenal levels of ANG II, which 178
shows very substantial compartmentalization and have been reported to be up to 1000 and 179 100 times plasma levels of ANG II, respectively (19, 143) . Conversely, data about the 180 natriuresis in response to furosemide in the absence and presence of inhibitors of the RAS 181 is limited and not consistent. Two studies indicated that the fractional sodium excretion 182 was diminished when the angiotensin-converting enzyme (ACEi) captopril was acutely7 administered before furosemide in humans with heart failure, however, the captopril dose 184 led to substantial hypotension (48, 101). Motwani et al (107) observed that an ultralow 185 dose of captopril (1 mg), which did not decrease MAP in HF patients, enhanced the 186 natriuretic actions of furosemide, whereas a higher dose (25 mg) decreased MAP and 187 attenuated the natriuresis. In a chronic setting, ACEi seems to enhance the natriuretic 188 response to furosemide in heart failure (53). It would be an interesting option to 189 specifically target the renal RAS (e.g. by using lysozyme-modified captopril (61) This is particularly relevant in conditions with fluid congestion and hypotension, such as8 advanced heart failure, in which furosemide would be applied. Altogether, furosemide can 215 impair renal autoregulation; whether this is relevant for sodium excretion is unknown. As 216 mentioned, furosemide can block the TGF system by inhibiting the sensing of the Cl -217 concentration in the macula densa. This would deactivate the TGF system and increase 218 single nephron GFR and thereby filtered load. Conversely, furosemide increases the macula 219 densa NaCl delivery and could activate the TGF system, depress GFR and diminish filtered 220 load. It is not clear whether tubular concentrations achieved by pharmacological use of 221 furosemide tip the balance between these opposing forces towards an attenuated or 222 activated TGF response. To illustrate this further, Figure 1 shows the response to low dose 223 administration of furosemide and of the carbonic anhydrase inhibitor acetazolamide in 224 healthy subjects. Acetazolamide led to a consistent increase in lithium clearance (which can 225 be used as estimate of distal delivery) and a consistent decrease in GFR. Furosemide led to 226 a highly variable response in GFR, although never clearly increased GFR. How GFR would 227 respond to furosemide in patients on multiple medications and with multiple co-228 morbidities is entirely unclear. 229
230

What determines the braking phenomenon and is there a fundamental difference with short-231 term furosemide resistance? 232
The braking phenomenon is the decrease in the response to furosemide after the first dose 233 (165), and is considered a physiological response to avoid ECFV contraction. Some data 234 suggest that it can be prevented by restoring the diuretic-induced loss of ECFV (21). 235
Confusingly, other data suggest that the braking phenomenon induced by the loop diuretic: 236 bumetanide, is volume independent (4). In short-term therapy, more pronounced volume 237 depletion will trigger more compensatory mechanisms to preserve the ECFV, which has 238 also been denoted as acute diuretic resistance (57). Both the braking phenomenon and 239 short-term resistance could be caused by post-diuretic Na + retention (7). This also happens 240 when furosemide is suddenly withdrawn (106). Dietary Na + is a critical factor (43): during 241 high Na + intake, the compensatory increase in Na + reabsorption between doses can lead to 242 neutral Na + balance; to achieve a negative Na + balance, a dietary Na + restriction is required 243 (7, 165 are, is not resolved. Moreover, at a more physiological level, it seems that there is an 317 intrinsic set point of the kidney for a certain degree of Na + reabsorption related to total 318 body sodium (132); while this might affect very local phenomena such as tubular fluid, 319 tubular osmolality, and interstitial composition, this might also feed back to the kidney by 320 neurohumoral mechanisms. 321
322
Why is the effect of furosemide on sodium balance, ECFV and blood pressure unpredictable? 323 ECFV expansion can increase total peripheral resistance and blood pressure by evoking 324 total body autoregulation in response to overperfusion of tissues. A logical approach to 325 reduce blood pressure is to reduce ECFV using diuretics. Verification of this concept would 326 require reliable and easily applicable ECFV measurements. Radio-isotope measures are 327 reliable but not easy to use. Mono-and multi-frequency bio-impedance measurements of 328 ECFV are reliable but have hardly been employed to research the subject. Only one study 329 documented a 1.1 L decrease in ECFV after initiation of furosemide therapy in patients with 330
CKD (compared to subjects treated with non-diuretic antihypertensives) (170). To obtain 331 insight into how furosemide affects ECFV regulation, further studies are needed to better 332 characterize who will benefit from furosemide therapy and which regimen (dose, dose 333 frequency, route of administration) is effective to reduce ECFV to normal. 334 335 Several studies in the 1970's indicate that once per day dosing of furosemide induces a 336 natriuresis over about 6-8h followed by sodium retention during the rest of the day (165). 337
The mechanism of this sodium retention has not been entirely resolved; it could be relatedto a) activation of the RAS, b) activation of the SNS and c) acute reduction in PV followed by 339 decreased renal perfusion pressure and 'pressure natriuresis'. A stronger natriuretic 340 response to furosemide would lead to a more pronounced decrease in PV. A decrease in PV 341 of 16% (580 ml) was observed in hypertensive subjects after 100-200 mg i.v. furosemide 342 (36). Of note, the stability of the effective circulating volume also is related to the refill rate 343 from the interstitial space, and the dynamics of the venous capacitance (see below). A study 344 in heart failure patients demonstrated a net refill volume (and perhaps also venous to 345 arterial fluid redistribution volume) exceeding the diuresis induced by furosemide (140). 346
Refill rate cannot be easily assessed, although a methodology has been developed to 347 measure refill rate in hemodialysis (24). Starling forces primarily determine refill rate and 348 include the permeability of the capillary membrane, which is not fixed but influenced by 349 numerous factors, including ANG II (168) 
Questions regarding hemodynamics and vascular regulation and the RAS 382
What determines the effects of furosemide on GFR and RBF? 383
In 18 studies about the actions of furosemide on GFR and RBF in healthy subjects, changes 384 in GFR and/or RBF were reported. In the majority of studies GFR increased 
Does kidney disease affect the actions of furosemide? 515
Whether furosemide is equally potent in healthy individuals versus patients with CKD is 516 related to the pharmacology of furosemide and the tubular mechanisms that lead to Na + 517 retention in CKD. Regarding the pharmacology, intestinal reabsorption of 40-90% has been 518 reported in subjects with advanced CKD (65) yet altogether reabsorption seems 519 diminished (154). Although a clear relationship between reabsorption and measures of>20h in some individuals. This could contribute to 'resistance' since in some subjects it 523 could accumulate so that additional dosages do not elicit a natriuresis. Conversely, having 524 plasma levels over a more sustained period could prevent resistance. Another 525 pharmacologic issue is that in states with high grade proteinuria, the glomerular filtrate 526 might contain so much albumin that it diminishes the free furosemide levels to such an 527 extent that this diminishes its actions (145). In that regard, it is noted that Brater showed 528 that displacing furosemide from plasma proteins with a sulphonomide (sulfisoxazole) did 529 not correct resistance in nephrotic patients (2). There is still controversy about whether 530 and how albumin infusion could increase the natriuretic actions of furosemide in the 531 nephrotic state (45). Taken together, diminished reabsorption, increased T½, and high-532 grade proteinuria in patients with CKD could limit the natriuretic response. 533 534 A more physiological issue is that when GFR declines in CKD, fractional excretion of Na + has 535 to increase in order to maintain Na + balance. A healthy subject with an estimated GFR of 536 120 ml/min/1.73m 2 therefore has a 10X lower fractional sodium excretion (0.5-1.0%) than 537 a subject with advanced CKD and an estimated GFR of 12 ml/min/1.73m 2 (5-10%) 538 assuming similar intake and assuming sodium balance. This leads to the important 539 question how the remnant nephrons in CKD decrease their Na + reabsorption. Since NKCC2-540 mediated reabsorption is so substantial, one option is that NKCC2 is suppressed. Data 541 about CKD and expression of NKCC2 is limited. One study demonstrated an initial increase 542 in NKCC2 expression after 5/6 th nephrectomy in rats, later returning towards normal (85). 543
Two studies in rats after uninephrectomy and salt loading demonstrated decreased 544 expression of the NKCC2 (73, 74). In DOCA-salt hypertension (8) NKCC2 seems to decrease, 545 while in ANG II-induced hypertension (110) NKCC2 seems only decreased in the renal 546 medulla. Altogether, data in renal failure about NKCC2 expression and activity is limited. 547
548
At a translational level, in relatively severe CKD, the natriuresis to 1.5 mg/kg furosemide in 549 CKD was directly proportional to GFR (inulin clearance) yet the increase in fractional Na + 550 and water excretion upon furosemide did not decline with lower GFR (54). Another reportindicated an increase in fractional Na + excretion to >40% upon high dose furosemide in 552 patients with very low GFR (4-8 ml/min/1.73 m 2 )(3). Lastly, one report indicated 553 maintained responses in urinary Na + excretion after furosemide given orally or 554 intravenously in patients with mild and with advanced(134) CKD, indicating an enhanced 555 response in fractional Na + excretion to furosemide. Therefore, experimental and human 556 data seem in conflict: whether there are humans with clearly decreased NKCC2 expression 557 and function and consequently diminished response to furosemide is unclear and whether 558 regulation of sodium transporters in CKD with different severity and aetiology is unclear. 559 560
Are effects of furosemide on urate levels detrimental for BP regulation and kidney integrity? 561
One of the most important side effects of diuretics is that it can provoke a gout attack. In recent years, the notion developed that Na + could distribute to cutaneous tissue, where it 588 could bind to glycosaminoglycans in a non-osmotic fashion (156). This non-osmotic sodium 589 possibly elicits an inflammation response, with release of VEGF-C as a consequence, which 590 would offset hypertensive consequences of high sodium intake (155). Gradually, evidence 591 is accumulating that the subcutaneous sodium storage is expanded in different disease 592 states such as hypertension (97) 
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